Advice
following a full submission
dalteparin (Fragmin®) is accepted for restricted use within NHS Scotland.
Indication under review: extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence in patients with solid tumours.
SMC restriction: initiation by healthcare professionals experienced in the treatment of VTE.
In patients with cancer and VTE, dalteparin significantly reduced the rates of VTE recurrence over a six month period, compared to oral anticoagulation. Bleeding and mortality rates for patients receiving dalteparin were similar to those reported in patients receiving oral anticoagulant.
The economic case was demonstrated for dalteparin compared to other low molecular weight heparins.
Download detailed advice122KB (PDF)
Medicine details
- Medicine name:
- dalteparin (Fragmin)
- SMC ID:
- 683/11
- Indication:
- Patients with solid tumours: extended treatment of symptomatic VTE and prevention of recurrence.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 March 2011